At Concert Pharmaceuticals, we create novel medicines to meet important healthcare needs by applying our DCE Platform® (Deuterated Chemical Entity Platform) technology to compounds with well-characterized pharmacological activity. This approach enables us to leverage decades of pharmaceutical expertise to greatly reduce R&D risk, time and expense.
Concert is a rapidly growing company with an entrepreneurial culture that transitioned to a clinical stage company only two years after its inception. Concert was co-founded by Richard Aldrich, Roger Tung and Christoph Westphal, and is located in the historic town of Lexington, Massachusetts.
Headquarters: Lexington, MA
Founded: April 2006
Equity Funding: $110 million
Investors: Top tier venture capital and leading institutional investors
Issued U.S. Patents: 39
CEO: Roger Tung, Ph.D.